Rubicon Research Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2026. The company reported a significant increase in both revenue and profit for the quarter compared to the previous quarter (QoQ) and the corresponding quarter of the previous year (YoY).

Rubicon Research is a pharmaceutical company focused on innovation, quality, and care. The company is primarily engaged in the single business segment of selling pharmaceutical products. In 2025, Rubicon Research completed its Initial Public Offering (IPO), and its equity shares were listed on the National Stock Exchange of India (NSE) and BSE Limited (BSE) on October 16, 2025. Additionally, in early 2026, the company incorporated a wholly-owned subsidiary, AdvaGen S.A. Company, in Saudi Arabia to engage in the trading of finished pharmaceutical products, and it entered into a definitive agreement to acquire a 65% stake in Anna Lifesciences Limited, which was completed on April 30, 2026.

For the quarter ended March 31, 2026, the company reported revenue from operations of 5,139.15 million and a net profit after tax of 767.85 million. The financial performance was bolstered by robust operational activities, though the company noted incremental costs related to the implementation of new labor codes in India. While the provided documents do not explicitly detail the current holding of famous investors, the company’s IPO in 2025 resulted in General Atlantic Singapore RR PTE Ltd no longer being a holding company.